NEW YORK – PerkinElmer announced on Wednesday that it has received the CE-IVD mark for its screening assay that simultaneously tests for spinal muscular atrophy (SMA), severe combined immunodeficiency (SCID), and X-linked agammaglobulinemia (XLA) in newborns.
The assay, called Eonis, leverages RT-PCR technology, which when integrated into the Waltham, Massachusetts-based firm's newborn screening workflow provides labs a complete, single-source solution, PerkinElmer said.
The assay can be automated with Janus Liquid Handlers to further streamline the workflow of high-throughput labs, and the traceable dried bloodspot workflow consists of five elements to detect SMA, SCID, and XLA – sample collection, punching , DNA extraction, amplification, and data analysis, PerkinElmer said.